Towards precision medicine: Leading with big data and multidisciplinary collaboration

Abstract

Precision medicine relies on individuals’ genetic information, omics characteristics, and environmental factors to achieve personalized disease prevention, diagnosis, and treatment. With the successful mapping of the entire human genome and the rise of various cutting-edge omics technologies, precision medicine has ushered in an era of accelerated development. However, there are still many challenges in the implementation of precision medicine, such as insufficient accumulation of clinical evidence, the complexity of data interpretation, and there is a long road ahead before it can be widely available. Close cooperation among multiple disciplines is necessary. Policy support, technological and methodological innovation in academia and industry, and competent precision medicine teams are important factors in the advancement and implementation of precision medicine. Precision prevention, diagnosis, and treatment of diseases require guidance from various levels of data, underscoring the value of big data in the era of precision medicine. It also imposes higher demands on physicians and pharmacists to be capable of prescribing the right drug to the right patient at the right time and at the right dose. The era of precision medicine will be a new era for them to demonstrate greater professional value.

Keywords

Precision medicine / Big data / Multidisciplinary collaboration

Declarations

Not applicable.

Authors' contributions

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This study was supported by grants from the National Natural Science Foundation of China (82173789 to H.D.).

Declaration of Competing Interest

The authors declare that they have no competing interests.

Acknowledgements

Not applicable.

Authors' other information

Not applicable.

References

[1] Konstantinidou MK, Karaglani M, Panagopoulou M, et al. Are the origins of precision medicine found in the corpus hippocraticum? Mol Diagn Ther. 2017; 21(6):601-606. https://doi.org/10.1007/s40291-017-0291-y

[2] Garrod AE. The Lancet. The incidence of alkaptonuria: a study in chemical individuality. Nutr Rev. 1975; 33(3):81-83. https://doi.org/10.1111/j.1753-4887.1975.tb06025.x

[3] Zhou HH, Koshakji RP, Silberstein DJ, et al. Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med. 1989; 320(9):565-570. https://doi.org/10.1056/NEJM198903023200905

[4] Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988; 331(6155):442-446. https://doi.org/10.1038/331442a0

[5] International International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature. 2004; 431(7011): 931-945. doi: 10.1038/nature03001.

[6] Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P 450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005; 106(1):135-140. https://doi.org/10.1182/blood-2005-01-0341

[7] Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015; 25(1):33-41. https://doi.org/10.1016/j.tcm.2014.09.001

[8] Carr DF, O'Meara H, Jorgensen AL, et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther. 2013; 94:695-701. https://doi.org/10.1038/clpt.2013.161

[9] Ramsey LB, Johnson SG, Caudle KE, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014; 96(4):423-428. https://doi.org/10.1038/clpt.2014.125

[10] MEGA JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010; 304(16):1821-1830. https://doi.org/10.1001/jama.2010.1543

[11] Scheffer IE, Nabbout R. SCN1A-related phenotypes: epilepsy and beyond. Epilepsia. 2019; 60(3):S17-S24. https://doi.org/10.1111/epi.16386

[12] Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011; 364(12):1126-1133. https://doi.org/10.1056/NEJMoa1009717

[13] Phillips EJ, Sukasem C, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clin Pharmacol Ther. 2018; 103(4):574-581. https://doi.org/10.1002/cpt.1004

[14] Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015; 98(2):127-134. https://doi.org/10.1002/cpt.147

[15] Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14):1273-1283. https://doi.org/10.1056/NEJMoa0910383

[16] Park JJH, Hsu G, Siden EG, et al. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 2020; 70(2):125-137. https://doi.org/10.3322/caac.21600

[17] Moore DC, Guinigundo AS. Biomarker-driven oncology clinical trials: novel designs in the era of precision medicine. J Adv Pract Oncol. 2023; 14(1):9-13. https://doi.org/10.6004/jadpro.2023.14.3.16

[18] Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017; 17(4):223-238. https://doi.org/10.1038/nrc.2017.7

[19] Mukherjee S. Genomics-guided immunotherapy for precision medicine in cancer. Cancer Biother Radiopharm. 2019; 34(8):487-497. https://doi.org/10.1089/cbr.2018.2758

[20] National Institutes of Health Consensus Development Pannel. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000. Pediatrics. 2001; 108(4): 972-982. doi: 10.1542/peds.108.4.972.

[21] Inouye M, Abraham G, Nelson CP, et al. Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention. J Am Coll Cardiol. 2018; 72(16):1883-1893. https://doi.org/10.1016/j.jacc.2018.07.079

[22] Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016; 15(7):473-484. https://doi.org/10.1038/nrd.2016.32

[23] Valdeolivas A, Amberg B, Giroud N, et al. Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics. NPJ Precis Oncol. 2024; 8(1):10. https://doi.org/10.1038/s41698-023-00488-4

[24] Kashyap PC, Chia N, Nelson H, et al. Microbiome at the frontier of personalized medicine. Mayo Clin Proc. 2017; 92(12):1855- 1864. https://doi.org/10.1016/j.mayocp.2017.10.004

[25] Chanchal DK, Chaudhary JS, Kumar P, et al. CRISPR-based therapies: revolutionizing drug development and precision medicine. Curr Gene Ther. 2024; 24(3):193-207. https://doi.org/10.2174/0115665232275754231204072320

[26] Schupack DA, Mars RAT, Voelker DH, et al. The promise of the gut microbiome as part of individualized treatment strategies. Nat Rev Gastroenterol Hepatol. 2022; 19:7-25. https://doi.org/10.1038/s41575-021-00499-1

[27] Haiser HJ, Gootenberg DB, Chatman K, et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science. 2013; 341(6143):295-298. https://doi.org/10.1126/science.1235872

[28] Kundu S, Ali MA, Handin N, et al. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis. J Exp Clin Cancer Res. 2021; 40(1):225. https://doi.org/10.1186/s13046-021-02025-2

[29] Passaro A, Al Bakir M, Hamilton EG, et al. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell. 2024; 187(7):1617-1635. https://doi.org/10.1016/j.cell.2024.02.041

[30] Guengerich FP. Cytochrome P450 2E1 and its roles in disease. Chem Biol Interact. 2020; 322:109056. https://doi.org/10.1016/j.cbi.2020.109056

[31] Rao RT, Scherholz ML, Androulakis IP. Modeling the influence of chronopharmacological administration of synthetic glucocorticoids on the hypothalamic-pituitary-adrenal axis. Chronobiol Int. 2018; 35(12):1619-1636. https://doi.org/10.1080/07420528.2018.1498098

[32] Lauschke VM, Zhou Y, Ingelman-Sundberg M. Pharmacogenomics beyond single common genetic variants: the way forward. Annu Rev Pharmacol Toxicol. 2024; 64:33-51. https://doi.org/10.1146/annurev-pharmtox-051921-091209

[33] Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012; 337(6096):816-821. https://doi.org/10.1126/science.1225829

[34] Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. N Engl J Med. 2021; 384(3):252-260.

[35] Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020; 367(6481):eaba7365. https://doi.org/10.1126/science.aba7365